A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults

NCT ID: NCT06493461

Last Updated: 2025-05-30

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-23
• Study Completion Date: 2025-03-31

Brief Summary

A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults

Detailed Description

Phase 1b, Multicenter, Open-Label, Multiple Ascending Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS135 Added to Background Pulmonary Arterial Hypertension (PAH) Therapy

Conditions

Pulmonary Arterial Hypertension (PAH)

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HS135

Subcutaneous Injection

Group Type: EXPERIMENTAL

HS135

Intervention Type: BIOLOGICAL

HS135 is dosed subcutaneously

Interventions

HS135

HS135 is dosed subcutaneously

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male and female patients, 18 years of age and older.

2. Body Mass Index (BMI) 18.5 and 40 kg/m2 and body weight at or below 120 kg

3. Documented diagnostic RHC at any time prior to screening.

4. Diagnosis of WHO PAH Group 1.

5. Symptomatic PAH classified as WHO FC II to IV.

6. Baseline RHC performed during the Screening Period documenting a minimum PVR of ≥ 5 Wood units (WU) or ≥ 400 dyn・sec・cm-5 and a pulmonary artery wedge pressure (PAWP) of ≤ 15 mmHg.

7. On stable doses of at least 2 background PAH therapies.

Exclusion Criteria

1. Left ventricular ejection fraction < 50% at screening.

2. Any symptomatic coronary disease events within 6 months of the screening visit.

3. Uncontrolled systemic hypertension.

4. History of restrictive, constrictive or congestive cardiomyopathy.

5. History of atrial septostomy.

6. Patients who have an abnormality in the Echocardiogram or in the 12-lead ECG that, in the opinion of the Investigator, increases the risk of participating in the study.

7. Pulmonary function test (PFT) values of forced vital capacity (FVC) and or FEV1 < 60% predicted at the screening visit or within 6 months prior to the screening visit.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

35Pharma Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Monique Champagne, M.Sc.

Role: STUDY_DIRECTOR

VP, Clinical Operations

Locations

Site-501

Edmonton, Alberta, Canada

Site-202

Greifswald, , Germany

Countries

Canada; Germany

Other Identifiers

HS135-002

Identifier Type: -

Identifier Source: org_study_id